Skye Bioscience Inc (SKYE)

[zenvesting]

Proprietary biosynthetic pharmaceutical compounds.

Here's a PR a out their intentions to use biosynthesis to more efficiently produce their target compounds:

Nemus Bioscience Announces License of Biosynthetic Technology from Teewinot Life Sciences to Manufacture its Proprietary Cannabinoid Molecules
12/20/2016
COSTA MESA, CA / ACCESSWIRE / December 20, 2016 / NEMUS Bioscience, Inc. (NMUS) announced it has signed a definitive license agreement for rights to Teewinot Life Sciences Corp.'s patented biosynthetic technology to produce NEMUS' proprietary cannabinoid molecules.

"Nemus is anticipating an era of hypergrowth in the pharmaceuticalized cannabinoid space and we believe that the biosynthetic technology that Teewinot has developed fits with our industry-disruptive approach to this therapeutic market," commented Brian Murphy, M.D., M.B.A., CEO and Chief Medical Officer of Nemus. "We believe that the use of standard cannabinoid molecules like tetrahydrocannabinol (THC) and cannabidiol (CBD) can be improved upon using re-engineered proprietary forms of the molecules to enhance physicochemical characteristics, resulting in improved activity and safety in a business model not solely dependent on orphan drug applications. We anticipate that the biosynthetic technology being advanced by Teewinot will provide API that is more cost-effective to produce than pure chemical synthesis or deriving the molecules from plants."

Jeffrey Korentur, CEO of Teewinot Life Sciences Corporation, stated, "Our wholly owned subsidiary, Full Spectrum Laboratories, Ltd., is working to bring disruptive technologies to the area of cannabinoid manufacturing. The Teewinot team is working with Albany Molecular Research, Inc. (NASDAQ:AMRI) to advance the scale-up of biosynthetically produced products, and AMRI already has a relationship with Nemus related to API manufacturing. Our patented biocatalytic production methods and equipment offer the potential to improve not only purity and variety, but also the speed and cost of producing cannabinoid molecules over traditional botanical extraction or chemical synthesis methods."

"Nemus looks forward to the versatility of biosynthetic manufacturing to help us manufacture other cannabinoids we are currently studying for indications such as pain management and anti-infectives, especially related to resistant bacterial infections like methicillin-resistant Staphylococcus aureus (MRSA)," reported Dr. Murphy.